Barclays Reaffirms Their Buy Rating on Boston Scientific (BSX)

In a report released today, Matt Miksic from Barclays maintained a Buy rating on Boston Scientific (BSX – Research Report), with a price target of $78.00. The company’s shares closed yesterday at $73.26.

According to TipRanks, Miksic is a 5-star analyst with an average return of 6.8% and a 60.00% success rate. Miksic covers the Healthcare sector, focusing on stocks such as Medtronic, Baxter International, and LivaNova.

In addition to Barclays, Boston Scientific also received a Buy from Truist Financial’s Richard Newitter in a report issued yesterday. However, on April 24, Deutsche Bank maintained a Hold rating on Boston Scientific (NYSE: BSX).

The company has a one-year high of $69.21 and a one-year low of $48.35. Currently, Boston Scientific has an average volume of 6.35M.

Based on the recent corporate insider activity of 108 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BSX in relation to earlier this year. Most recently, in February 2024, Edward Ludwig, a Director at BSX sold 7,000.00 shares for a total of $455,210.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Boston Scientific (BSX) Company Description:

Boston Scientific Corporation engages in the manufacturing of medical devices and products that are used in various interventional medical specialties worldwide. The company provides implantable devices including heart monitors, technologies for treating coronary artery disease and other cardiovascular disorders, and devices for diagnosing and treating gastrointestinal and pulmonary problems.